Key facts
- Kingdom Therapeutics’s last known valuation is $13.3M (Jul 2023).
- It has raised $940K; the latest was Later Stage VC in Jan 2025.
- Notable investors include 5 Horizons Capital, Celadon Pharmaceuticals.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kingdom Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Kingdom Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kingdom Therapeutics
Developer of autism spectrum disorder (ASD) drugs intended to create a link between the gut, the brain, and the endocannabinoid system. The company's cannabinoid based treatment utilises a delivery methodology that improves bioavailability and, by bypassing the liver, has the potential to reduce adverse effects, enabling ASD children to improve both behavioural and gastrointestinal symptoms in ASD.
- Sector
- Healthcare
- HQ
- Ireland
- Founded
- 2019
- Employees
- 9
- Website
- kingdomtherapeutics.com/
- Ownership
- Privately Held (backing)
Kingdom Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kingdom Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kingdom Therapeutics in its N-PORT filings yet. We sweep new filings monthly.